Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use TAMIFLU safely and effectively. See full prescribing information for TAMIFLU. TAMIFLU® (oseltamivir phosphate) capsules TAMIFLU® (oseltamivir phosphate) for oral suspension Initial U.S. Approval: 1999
Medication labelWhy this: Advisory · dailymed-prescription
TAMIFLU is indicated for the treatment of uncomplicated acute illness due to influenza infection in patients 1 year and older who have been symptomatic for no more than 2 days. TAMIFLU is indicated for the prophylaxis of influenza in patients 1 year and older. The following points should be considered before initiating treatment or prophylaxis with TAMIFLU: Efficacy of TAMIFLU in patients who begin treatment after 48 hours of symptoms has not been established. TAMIFLU is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. There is no evidence for efficacy of TAMIFLU in any illness caused by agents other than influenza viruses types A and B. Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use TAMIFLU.
- generic_name
- oseltamivir phosphate
- product_names
- Oseltamivir Phosphate, oseltamivir phosphate
- ndc
- 54868-6315, 0004-0820, 54868-6315-0, 54868-6083, 0004-0801, 54868-6083-0, 54868-4476, 0004-0800, 54868-4476-0
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en